Literature DB >> 12203785

A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome.

María D Odero1, José L Vizmanos, José P Román, Idoya Lahortiga, Carlos Panizo, María J Calasanz, Nancy J Zeleznik-Le, Janet D Rowley, Francisco J Novo.   

Abstract

ETV6/TEL is the first transcription factor identified that is specifically required for hematopoiesis within the bone marrow. This gene has been found to have multiple fusion partners of which 16 have been cloned. Fluorescence in situ hybridization (FISH) analysis in a patient with myelodysplastic syndrome (MDS) revealed a t(1;12)(p36;p13) involving ETV6, with the breakpoint in this gene between exon 2 and exon 3. We report here the cloning of a novel ETV6 partner located on 1p36.1, involved in the t(1;12). 3' RACE-PCR from RNA identified a novel sequence fused to exon 2 of ETV6. Database searches localized this sequence in a bacterial artificial chromosome (BAC) mapped to 1p36 by fingerprint analysis. This result was confirmed by FISH using this BAC as probe. 5' and 3' RACE experiments with primers from this novel sequence were carried out on RNA from a healthy donor and identified a novel full-length mRNA, which we named MDS2 (myelodysplastic syndrome 2). RT-PCR experiments were performed on a panel of human cDNAs to analyze the expression pattern of this gene and they revealed four splicing variants. RT-PCR analysis showed that ETV6-MDS2, but not the reciprocal MDS2-ETV6 fusion transcript, was expressed in the bone marrow of the patient. The product of the ETV6-MDS2 fusion transcript predicts a short ETV6 protein containing the first 54 amino acids of ETV6 plus four novel amino acids, lacking both the PTN and the DNA-binding domains. Possible mechanisms to account for the development of MDS in this patient are discussed. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203785     DOI: 10.1002/gcc.10090

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

2.  Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.

Authors:  Michaela Dostalova Merkerova; Zdenek Krejcik; Hana Votavova; Monika Belickova; Alzbeta Vasikova; Jaroslav Cermak
Journal:  Eur J Hum Genet       Date:  2010-12-08       Impact factor: 4.246

Review 3.  Current treatment options: impact of cytogenetics on the course of myelodysplasia.

Authors:  Naomi Galili; Jan Cerny; Azra Raza
Journal:  Curr Treat Options Oncol       Date:  2007-04

4.  Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies.

Authors:  Francois P Duhoux; Geneviève Ameye; Virginie Lambot; Christian Herens; Frédéric Lambert; Sophie Raynaud; Iwona Wlodarska; Lucienne Michaux; Catherine Roche-Lestienne; Elise Labis; Sylvie Taviaux; Elise Chapiro; Florence Nguyen-Khac; Florence Nguyen Khac; Stéphanie Struski; Sophie Dobbelstein; Nicole Dastugue; Eric Lippert; Frank Speleman; Nadine Van Roy; An De Weer; Katrina Rack; Pascaline Talmant; Steven Richebourg; Francine Mugneret; Isabelle Tigaud; Marie-Joëlle Mozziconacci; Sophy Laibe; Nathalie Nadal; Christine Terré; Jeanne-Marie Libouton; Anabelle Decottignies; Miikka Vikkula; Hélène A Poirel
Journal:  PLoS One       Date:  2011-10-21       Impact factor: 3.240

5.  FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome.

Authors:  Idoya Lahortiga; Iria Vázquez; Elena Belloni; José P Román; Patrizia Gasparini; Francisco J Novo; Isabel Zudaire; Pier G Pelicci; Jesús M Hernández; María J Calasanz; María D Odero
Journal:  Hum Genet       Date:  2005-03-03       Impact factor: 4.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.